)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Integrum
Integrum (INTEG) investor relations material
Integrum Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary3 Sep, 2026
Executive summary
Achieved strong growth and improved profitability in the first quarter, with S1 surgeries up 17% year-over-year and net sales rising 27% to SEK 30.2 million.
Strategic shift towards a more commercial and scalable business model is yielding results, with a positive EBITDA of SEK 3.8 million compared to SEK -10.7 million last year.
Expansion of digital patient platform in the US and ongoing launches in Ukraine and Germany are driving patient flow and operational efficiency.
Financial highlights
Net sales increased 27% year-over-year to SEK 30.2 million, with US sales up 22% and EMEA up 51%.
Gross margin reached 102% due to a SEK 6.2 million US customs duty refund; adjusted gross margin was 82% (vs. 80% last year).
EBITDA was SEK 3.8 million (vs. SEK -10.7 million), or SEK -2.4 million excluding the customs refund.
Operating profit was SEK 1.3 million (vs. SEK -12.4 million).
Operating cash flow was SEK -2.2 million (vs. SEK -9.5 million).
Outlook and guidance
Focus remains on accelerating patient acquisition, improving conversion rates, and expanding S1 surgeries.
Continued investment in commercial infrastructure and next-generation bionics technology.
Management targets sustainable, profitable growth and scalability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Integrum
- Record S1 surgeries and cost controls set the stage for improved future performance.INTEG
Q4 25/26 - Q3 sales fell 14.8% but cost cuts and new funding set the stage for improved profitability.INTEGQ3 25/26
- Sales up 2.6% in Q2, net loss narrows, US drives growth; rights issue to fund expansion.INTEGQ2 25/26
- Net sales rose 28.9% and US sales grew 41%, but gross margin fell due to tariffs.INTEGQ1 25/26
- Q2 sales fell 21% year-over-year, but sequential growth and new financing support recovery.INTEGQ2 24/25
- Focus on sales productivity, targeted launches, and operational discipline to drive recovery.INTEGInvestor update
- Sales fell 9.5% as losses widened, but US deals and capital raise support future growth.INTEGQ1 24/25
- US-driven growth offsets overall sales decline as Integrum accelerates OPRA® commercialization.INTEGQ4 24/25
- Sales fell 21% year-over-year; U.S. focus, cost controls, and new funding drive growth.INTEGQ3 24/25
Next Integrum earnings date
Q4 202611 Feb, 2027
Integrum
Next Integrum earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Integrum AB researches, develops, and sells various systems for bone-anchored prostheses. It specializes in systems for rehabilitation of patients who lose a limb as a result of cancer or a trauma. The company also generates revenues through the sale of spare parts, instruments, implants, and material for bone surgery related to the use of its products. The company offers their products to surgical professionals in selected markets worldwide.